Probiotics for obesity: a new clinical trial

Probiotics for obesity: a new clinical trial

This randomized, double-blinded and placebo-controlled study examined the effects of MED-02, a combination of two Limosilactobacillus fermentum strains (MG4231 and MG4244) in overweight or obese subjects. 100 participants have been recruited and received the placebo or MED02 (5 x 10(9) CFU/day) for 12 weeks.

Reductions in body fat mass (-1166.82 g vs. -382.08 g; p = 0.024) and body fat percentage (-0.85% vs. -0.11%; p = 0.030) have been measured, as a reduction in body weight (-2.06 kg vs. -1.22 kg; p = 0.041). No side effect has been noted, suggesting that the probiotics are safe and effective for the management of body weight.

Cho YG, Yang YJ, Yoon YS, Lee ES, Lee JH, Jeong Y, Kang CH. Effect of MED-02 Containing Two Probiotic Strains, Limosilactobacillus fermentum MG4231 and MG4244, on Body Fat Reduction in Overweight or Obese Subjects: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study. Nutrients. 2022 Aug 30;14(17):3583.